OBJECTIVES: To investigate the expression profile of programmed death-1 (PD-1) on T cells derived from patients with cutaneous T-cell lymphoma (CTCL), analyze a potential mechanism responsible for upregulation of PD-1, and assess the correlation between blockade of its signaling pathway and improvement in immunological function. DESIGN: Translation research study. SETTING: University medical center. PARTICIPANTS: Patients with Sézary syndrome, patients with mycosis fungoides, and healthy volunteers. MAIN OUTCOME MEASURES: Programmed death-1 expression on T cells by flow cytometry and interferon γ (IFN-γ) production by enzyme-linked immunosorbent assay. RESULTS: We report significantly increased PD-1 expression on CD4(+) T cells from patients with Sézary syndrome compared with CD4(+) T cells from patients with mycosis fungoides and healthy volunteers. Both CD26(-) and CD26(+) populations of CD4(+) T cells demonstrated increased expression of PD-1, which was upregulated by the engagement of the T-cell receptor with anti-CD3/CD28 antibodies. In addition, blockade of the signaling pathway with blocking antibodies to PD-1 or its ligand PD-L1 led to an increase in the capacity to produce IFN-γ among some patients. Finally, longitudinal studies of 1 patient revealed a progressive decrease in PD-1 expression on CD4(+) T cells with improvement of clinical disease. CONCLUSION: Our data imply that increased PD-1 expression in Sézary syndrome may play a role in attenuating the immune response and provide further insight into the immunosuppressive nature of CD4(+) T cells in Sézary syndrome and suggest another potential means of targeted therapy for these patients.
OBJECTIVES: To investigate the expression profile of programmed death-1 (PD-1) on T cells derived from patients with cutaneous T-cell lymphoma (CTCL), analyze a potential mechanism responsible for upregulation of PD-1, and assess the correlation between blockade of its signaling pathway and improvement in immunological function. DESIGN: Translation research study. SETTING: University medical center. PARTICIPANTS: Patients with Sézary syndrome, patients with mycosis fungoides, and healthy volunteers. MAIN OUTCOME MEASURES: Programmed death-1 expression on T cells by flow cytometry and interferon γ (IFN-γ) production by enzyme-linked immunosorbent assay. RESULTS: We report significantly increased PD-1 expression on CD4(+) T cells from patients with Sézary syndrome compared with CD4(+) T cells from patients with mycosis fungoides and healthy volunteers. Both CD26(-) and CD26(+) populations of CD4(+) T cells demonstrated increased expression of PD-1, which was upregulated by the engagement of the T-cell receptor with anti-CD3/CD28 antibodies. In addition, blockade of the signaling pathway with blocking antibodies to PD-1 or its ligand PD-L1 led to an increase in the capacity to produce IFN-γ among some patients. Finally, longitudinal studies of 1 patient revealed a progressive decrease in PD-1 expression on CD4(+) T cells with improvement of clinical disease. CONCLUSION: Our data imply that increased PD-1 expression in Sézary syndrome may play a role in attenuating the immune response and provide further insight into the immunosuppressive nature of CD4(+) T cells in Sézary syndrome and suggest another potential means of targeted therapy for these patients.
Authors: Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer Journal: Blood Date: 2005-02-03 Impact factor: 22.113
Authors: Christian Blank; Juergen Kuball; Simon Voelkl; Heinz Wiendl; Bernd Becker; Bernhard Walter; Otto Majdic; Thomas F Gajewski; Mathias Theobald; Reinhard Andreesen; Andreas Mackensen Journal: Int J Cancer Date: 2006-07-15 Impact factor: 7.396
Authors: Jens M Chemnitz; Daniela Eggle; Julia Driesen; Sabine Classen; James L Riley; Svenja Debey-Pascher; Marc Beyer; Alexey Popov; Thomas Zander; Joachim L Schultze Journal: Blood Date: 2007-07-20 Impact factor: 22.113
Authors: Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup Journal: J Exp Med Date: 2006-09-05 Impact factor: 14.307
Authors: Nicholas Borcherding; Andrew P Voigt; Vincent Liu; Brian K Link; Weizhou Zhang; Ali Jabbari Journal: Clin Cancer Res Date: 2019-02-04 Impact factor: 12.531
Authors: Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544
Authors: Sharrón L Manuel; Mohit Sehgal; John Connolly; George Makedonas; Zafar K Khan; Jay Gardner; Michael R Betts; Pooja Jain Journal: J Clin Immunol Date: 2013-07-26 Impact factor: 8.317
Authors: Carolyn S Lee; Alexander Ungewickell; Aparna Bhaduri; Kun Qu; Dan E Webster; Randall Armstrong; Wen-Kai Weng; Cody J Aros; Angela Mah; Richard O Chen; Meihong Lin; Uma Sundram; Howard Y Chang; Markus Kretz; Youn H Kim; Paul A Khavari Journal: Blood Date: 2012-08-30 Impact factor: 22.113